These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 25190600)

  • 41. Microbiota and prebiotics modulation of uremic toxin generation.
    Koppe L; Fouque D
    Panminerva Med; 2017 Jun; 59(2):173-187. PubMed ID: 28001024
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Immunomodulatory Effect of the Gut Microbiota in Kidney Disease.
    Chi M; Ma K; Wang J; Ding Z; Li Y; Zhu S; Liang X; Zhang Q; Song L; Liu C
    J Immunol Res; 2021; 2021():5516035. PubMed ID: 34095319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intestinal microbiome and fitness in kidney disease.
    Meijers B; Evenepoel P; Anders HJ
    Nat Rev Nephrol; 2019 Sep; 15(9):531-545. PubMed ID: 31243394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intestinal Barrier Function in Chronic Kidney Disease.
    Meijers B; Farré R; Dejongh S; Vicario M; Evenepoel P
    Toxins (Basel); 2018 Jul; 10(7):. PubMed ID: 30029474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic kidney disease and the gut microbiome.
    Hobby GP; Karaduta O; Dusio GF; Singh M; Zybailov BL; Arthur JM
    Am J Physiol Renal Physiol; 2019 Jun; 316(6):F1211-F1217. PubMed ID: 30864840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Microbiota and the nitrogen cycle: Implications in the development and progression of CVD and CKD.
    Briskey D; Tucker PS; Johnson DW; Coombes JS
    Nitric Oxide; 2016 Jul; 57():64-70. PubMed ID: 27164294
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity.
    Vaziri ND
    Curr Opin Nephrol Hypertens; 2012 Nov; 21(6):587-92. PubMed ID: 23010760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intestinal barrier disruption and dysregulated mucosal immunity contribute to kidney fibrosis in chronic kidney disease.
    Yang J; Lim SY; Ko YS; Lee HY; Oh SW; Kim MG; Cho WY; Jo SK
    Nephrol Dial Transplant; 2019 Mar; 34(3):419-428. PubMed ID: 29939312
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Micro-inflammation and digestive bacterial translocation in chronic kidney disease].
    Olivier V; Dunyach-Remy C; Lavigne JP; Moranne O
    Nephrol Ther; 2018 May; 14(3):135-141. PubMed ID: 29295767
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Urea and impairment of the Gut-Kidney axis in Chronic Kidney Disease.
    Di Iorio BR; Marzocco S; Nardone L; Sirico M; De Simone E; Di Natale G; Di Micco L
    G Ital Nefrol; 2017 Dec; 34(Nov-Dec):. PubMed ID: 29207222
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Impact of Chronic Intestinal Inflammation on Brain Disorders: the Microbiota-Gut-Brain Axis.
    Serra D; Almeida LM; Dinis TCP
    Mol Neurobiol; 2019 Oct; 56(10):6941-6951. PubMed ID: 30945157
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gut microbiota, hypertension and chronic kidney disease: Recent advances.
    Sircana A; De Michieli F; Parente R; Framarin L; Leone N; Berrutti M; Paschetta E; Bongiovanni D; Musso G
    Pharmacol Res; 2019 Jun; 144():390-408. PubMed ID: 29378252
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chronic Kidney Disease, Gut Dysbiosis, and Constipation: A Burdensome Triplet.
    Ikee R; Sasaki N; Yasuda T; Fukazawa S
    Microorganisms; 2020 Nov; 8(12):. PubMed ID: 33255763
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic kidney disease after 5/6 nephrectomy disturbs the intestinal microbiota and alters intestinal motility.
    Nishiyama K; Aono K; Fujimoto Y; Kuwamura M; Okada T; Tokumoto H; Izawa T; Okano R; Nakajima H; Takeuchi T; Azuma YT
    J Cell Physiol; 2019 May; 234(5):6667-6678. PubMed ID: 30317589
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Short-chain fatty acids: a link between prebiotics and microbiota in chronic kidney disease.
    Esgalhado M; Kemp JA; Damasceno NR; Fouque D; Mafra D
    Future Microbiol; 2017 Nov; 12():1413-1425. PubMed ID: 29027814
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications.
    Natividad JM; Verdu EF
    Pharmacol Res; 2013 Mar; 69(1):42-51. PubMed ID: 23089410
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gut microbiota-related complications in cirrhosis.
    Gómez-Hurtado I; Such J; Sanz Y; Francés R
    World J Gastroenterol; 2014 Nov; 20(42):15624-31. PubMed ID: 25400446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease.
    Compare D; Coccoli P; Rocco A; Nardone OM; De Maria S; Cartenì M; Nardone G
    Nutr Metab Cardiovasc Dis; 2012 Jun; 22(6):471-6. PubMed ID: 22546554
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease.
    Fernandez-Prado R; Esteras R; Perez-Gomez MV; Gracia-Iguacel C; Gonzalez-Parra E; Sanz AB; Ortiz A; Sanchez-Niño MD
    Nutrients; 2017 May; 9(5):. PubMed ID: 28498348
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Role of Gut Dysbiosis in the Bone-Vascular Axis in Chronic Kidney Disease.
    Evenepoel P; Dejongh S; Verbeke K; Meijers B
    Toxins (Basel); 2020 Apr; 12(5):. PubMed ID: 32365480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.